

CHAPTER I - LAW OF 2 MARCH 1989

**Form B : subsequent declaration of interest held in a listed company
consequently a percentage change or updating¹****0. To be sent to:**

- the listed company concerned
- Banking, Finance and Insurance Commission
Supervision of Financial Information and Markets
For the attention of Mr. G. Delaere
Rue du Congrès 12-14, 1000 BRUSSELS - BELGIUM
Fax: +32 2 220 59 03 – e-mail: fmi.fin@cbfa.be

1. Name of company concerned : Omega Pharma N.V.**2. Details of the person making the declaration² in the capacity as declarant acting for own account / in the capacity as declarant acting on behalf of a third party³ / in the capacity as agent⁴***a) natural person*

surname + first name	Not applicable
address	Not applicable
phone number (optional)	Not applicable

b) legal person

legal form + company name	N.V. Omega Pharma
registered office	Venecoweg 26 B-9810 Nazareth
phone number	09/381.02.15
fax number	09/381.02.78
name and capacity of the signatory of the declaration	Barbara De Saedeleer Chief Financial Officer, Omega Pharma N.V.

3. Items covered by the declarationPreliminary remarks

Where the declaration is made by related persons or persons acting in concert, tables I and II shall be completed as many times as necessary:

- first for each of these persons *separately*, even where none of them reach a threshold as defined by law (see Article 8, § 1, 3°, of the Royal Decree of 10 May 1989)⁵;
- then for the *group* of related persons or persons acting in concert (see Article 2, §§ 1 and 2, of the Law of 2 March 1989).

¹ See Article 8, § 2, and Article 8, § 4, of the Royal Decree of 10 May 1989.

² Cross out what is not appropriate.

³ I.e. where a third party holds rights for the account of another person.

⁴ Each time a person who is subject to declaration entrusts this task to another person.

⁵ Except in the case of natural persons acting in concert none of whom possess a number of securities representing 5% or more of effective voting rights: these may make a joint declaration, without indicating the individual holders (Article 2, § 3, paragraph 2, of the Law of 2 March 1989).

Table I : general information

Name of the company concerned	Omega Pharma N.V.
Rights held by / for the account of ¹ (cross out what is not appropriate)	N.V. Omega Pharma, Venecoweg 26, B-9810 Nazareth
Related to	Not applicable
Acting in concert with	Not applicalbe
Date of completion of the situation giving rise to the declaration	12 November 2007: Purchase of 250.000 treasury shares 23 November 2007: Purchase of 100.000 treasury shares 30 November 2007: Purchase of 200.000 treasury shares
Sources relating to the denominator	Omega Pharma N.V.

¹ Where a third party holds rights for the account of another person.

* For natural persons: surname and first name + address; for legal persons: legal form, company name and address of registered office.

Table II : calculation of the stake

	previous declaration		modification (+ or -)	new declaration	
	numerator	% ²		numerator	numerator
1. Effective voting rights attaching to securities					
• representing the capital	272,794	1.04%	+ 550,000	822,794	3.14%
• not representing the capital					
2. Future voting rights , potential or not, resulting from					
• rights and commitments for conversion into or subscription of securities to be issued , viz.:					
◇ bond conversions					
◇ loan conversions					
◇ exercise of warrants					
◇ others (give details as appropriate)					
• rights and commitments for acquisition of issued securities , viz.:					
◇ options					
◇ warrants relating to issued securities					
◇ commitments arising from a contract					
◇ others (give details as appropriate)					
Total	272,794	1.03%	+ 550,000	822,794	3.11%
Mention					
Rights and commitments for conversion into, subscription of or acquisition of securities, subject to conditional clauses:					
• bond conversion					
• exercise of warrants					
• others (give details as appropriate)					
For rights and commitments from which future voting rights may arise, please specify the waiting or exercise period					
(Type + waiting/exercise period)					

² This percentage is to be calculated on the basis of the denominator used in the preceding declaration.

4. Description of the denominator

1. Effective voting rights attaching to securities <ul style="list-style-type: none"> • representing the capital • not representing the capital 	<ul style="list-style-type: none"> ▪ 26,202,798 ▪ not applicable
2. Future voting rights , potential or not, resulting from rights and commitments for conversion into or subscription of securities to be issued , viz.: <ul style="list-style-type: none"> ◇ bond conversions ◇ loan conversions ◇ exercise of warrants ◇ others (give details as appropriate) 	<ul style="list-style-type: none"> ▪ not applicable ▪ not applicable ▪ 224,719 ▪ not applicable
Total	26,427,517

5. Additional information to be provided if the number of securities held is equal to or greater than 20 % (see Article 8, § 1, paragraph 3, of the Royal Decree of 10 May 1989)

a. Description of the overall strategy in the course of which the acquisition or sale is made:

b. Number of securities rights acquired during the 12 months preceding this declaration, and manner of acquisition:

	number	manner of acquisition
1. Effective voting rights attaching to securities <ul style="list-style-type: none"> • representing capital • not representing capital 		
2. Future voting rights , potential or not, resulting from <ul style="list-style-type: none"> • rights or commitments for conversion into or subscription of securities to be issued, viz.: <ul style="list-style-type: none"> ◇ bond conversions ◇ loan conversions ◇ exercise of warrants ◇ others (give details as appropriate) • rights and commitments for subscription or acquisition of issued securities, viz.: <ul style="list-style-type: none"> ◇ options ◇ warrants relating to issued securities ◇ commitments arising from a contract ◇ others (give details as appropriate) 		

6. Description, possibly in the form of an organizational chart, of the structure of control of the company(ies) subject to declaration (optional)

Done on .3rd of December 2007 in Nazareth, Belgium.

... ..

(signature)

Barbara De Saedeleer,
Permanent vertegenwoordiger van
BDS Management b.v.b.a.
Chief Financial Officer
Omega Pharma N.V.

Annexes to be sent only to the Banking, Finance and Insurance Commission (mandatory by virtue of Article 4, § 1, paragraph 1, of the Law of 2 March 1989): the documents relating to the operation(s) giving rise to the declaration.